- Report
- February 2021
- 360 Pages
United States
From €2320EUR$2,400USD£1,994GBP
- Report
- February 2019
- 105 Pages
Global
From €1247EUR$1,290USD£1,072GBP
- Drug Pipelines
- June 2019
- 579 Pages
Global
€21268EUR$22,000USD£18,280GBP
- Report
- June 2019
- 18 Pages
Global
€9667EUR$10,000USD£8,309GBP
- Report
- January 2019
- 717 Pages
Global
From €21268EUR$22,000USD£18,280GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €483EUR$500USD£415GBP
- Report
- January 2019
- 35 Pages
Global
From €967EUR$1,000USD£831GBP
- Report
- June 2019
- 26 Pages
Global
€9667EUR$10,000USD£8,309GBP
- Report
- February 2024
- 87 Pages
Global
From €3500EUR$3,878USD£3,114GBP
Reyataz (atazanavir) is an antiretroviral drug used to treat HIV infection. It is a protease inhibitor, which works by blocking the action of the HIV protease enzyme, preventing the virus from replicating. Reyataz is usually used in combination with other antiretroviral drugs to treat HIV infection. It is also used to prevent HIV infection in people who are at high risk of becoming infected.
Reyataz is marketed by Bristol-Myers Squibb and is available in both capsule and oral suspension forms. It is approved for use in adults and children over the age of three months. The drug is also available in combination with other antiretroviral drugs, such as Truvada and Norvir.
The Reyataz market is highly competitive, with several companies offering similar products. These include Gilead Sciences, Merck & Co., GlaxoSmithKline, and Pfizer. Other companies, such as Mylan and Teva Pharmaceuticals, also offer generic versions of Reyataz. Show Less Read more
